Vivimed receives export order for supply of 'Favulous' tablets 200 mg - Favipiravir

Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today, the manufacturing of "Favulous" tablets 200 mg (Favipiravir) against export order. Favulous tablets 200 mg (Favipiravir) is used for the treatment of mild to moderate cases of Covid-19 . Favipiravir is the only oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate Covid-19 disease. The initial Export order Value is worth over INR 100 Million. we expect to receive further repeat orders during the Year.

Commenting on the launch, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "With over 300,000 Covid-19 cases being reported daily thought out the world, there is an urgent need to provide more treatment options to healthcare professionals. We are launching "Favulous" at an economical price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with our continuous efforts to support world's pandemic response."

The company will work closely with the various governments and medical community to ensure availability of "Favulous" to patients across the world.

Shares of VIVIMED LABS LTD. was last trading in BSE at Rs.12.23 as compared to the previous close of Rs. 11.65. The total number of shares traded during the day was 9849 in over 30 trades.

The stock hit an intraday high of Rs. 12.23 and intraday low of 12.2. The net turnover during the day was Rs. 120438.

Source : Equity Bulls

Keywords